S. Kornblau

Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities.

E. Estey, M. Konopleva, A. Mikhail, 1999, Blood.

Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid

John Calvin Reed, M. Konopleva, Z. Estrov, 1999, Leukemia.

Production and culture of HSVtk transduced suicidal lymphocytes induces variable changes in the lymphocyte subset composition

S. Kornblau, F. Marini, 1999, Bone Marrow Transplantation.

Ratio of bcl-xshort to bcl-xlong Is Different in Good- and Poor-Prognosis Subsets of Acute Myeloid Leukemia

S. Kornblau, S. Kornblau, A. Deisseroth, 1998, Molecular medicine.

Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects.

S. Kornblau, M. Andreeff, M. Milella, 2005, Current pharmaceutical design.

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.

E. Estey, M. Konopleva, Z. Estrov, 2001, The Journal of clinical investigation.

HOX expression patterns identify a common signature for favorable AML

K. Coombes, S. Kornblau, M. Andreeff, 2008, Leukemia.

Apoptosis. Molecules and mechanisms.

M. Konopleva, Z. Estrov, S. Zhao, 1999, Advances in experimental medicine and biology.

Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia.

P. Thall, Z. Estrov, D. Harris, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeted therapy of AML new concepts.

G. Mills, E. Estey, John Calvin Reed, 2004, Annals of hematology.

P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA

S. Kornblau, M. Andreeff, F. Ravandi, 2022, HemaSphere.